Hepatitis C Interim Study Results Favorable for TMC435
Share
Follow Us
Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
– Data show high antiviral activity, safety and tolerability comparable to placebo
BOSTON, Oct. 30 /PRNewswire/ — Tibotec Pharmaceuticals (Tibotec) announced today the company will present the results of a Week-24 planned interim analysis of the phase 2 response-guided PILLAR study in treatment-naive patients with chronic genotype 1 hepatitis C virus (HCV) at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA., USA. The data will be presented as part of a late-breaker oral presentation on Monday, November 1.
The results showed that in the four TMC435 treatment groups between 79 and 86 percent of patients were able to stop all therapy at Week-24, according to the response criteria defined in the study protocol. There were no relevant differences for adverse events between TMC435 treatment groups and placebo. TMC435, a hepatitis C protease inhibitor, dosed once daily (q.d.) is being developed jointly by Tibotec Pharmaceuticals and Medivir.
Continue reading this entire article:
http://www.prnewswire.com/news-releases/week-24-interim-results-from-phase-2b-pillar-study-to-be-presented-as-late-breaker-at-aasld-106368748.html
